phosphorylcholine has been researched along with Leukemia in 14 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objective of this phase I study was to determine the maximum tolerated dose (MTD) of UCN-01 given in combination with perifosine in patients with advanced acute leukemias and myelodysplastic syndrome." | 9.17 | Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. ( Baer, MR; Bauer, KS; Carroll, M; Fleckinger, S; Gojo, I; Luger, S; Norsworthy, KJ; Perl, A; Sausville, EA; Tidwell, M, 2013) |
| "Interactions between histone deacetylase inhibitors (HDACIs) and the alkyl-lysophospholipid perifosine were examined in human leukemia cells." | 7.73 | Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. ( Bauer, C; Dai, Y; Dent, P; Grant, S; Payne, SG; Rahmani, M; Reese, E; Spiegel, S, 2005) |
| "The primary objective of this phase I study was to determine the maximum tolerated dose (MTD) of UCN-01 given in combination with perifosine in patients with advanced acute leukemias and myelodysplastic syndrome." | 5.17 | Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. ( Baer, MR; Bauer, KS; Carroll, M; Fleckinger, S; Gojo, I; Luger, S; Norsworthy, KJ; Perl, A; Sausville, EA; Tidwell, M, 2013) |
| "Interactions between histone deacetylase inhibitors (HDACIs) and the alkyl-lysophospholipid perifosine were examined in human leukemia cells." | 3.73 | Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. ( Bauer, C; Dai, Y; Dent, P; Grant, S; Payne, SG; Rahmani, M; Reese, E; Spiegel, S, 2005) |
| "D-19391 was added to the SK-BR-3 breast cancer cell line and HePC to the Molt-4 leukemia cell line in concentrations of, respectively, 18." | 1.30 | Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography. ( Brochez, V; De Potter, CR; Diniz, JA; Van den Eeckhout, EG; Van Heuverswyn, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (57.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gojo, I | 1 |
| Perl, A | 1 |
| Luger, S | 1 |
| Baer, MR | 1 |
| Norsworthy, KJ | 1 |
| Bauer, KS | 1 |
| Tidwell, M | 1 |
| Fleckinger, S | 1 |
| Carroll, M | 1 |
| Sausville, EA | 1 |
| Voltan, R | 2 |
| Celeghini, C | 2 |
| Melloni, E | 1 |
| Secchiero, P | 1 |
| Zauli, G | 2 |
| Rimondi, E | 1 |
| Gattei, V | 1 |
| Wang, Y | 1 |
| Chen, L | 1 |
| Ding, Y | 1 |
| Yan, W | 1 |
| Thomé, CH | 1 |
| dos Santos, GA | 1 |
| Ferreira, GA | 1 |
| Scheucher, PS | 1 |
| Izumi, C | 1 |
| Leopoldino, AM | 1 |
| Simão, AM | 1 |
| Ciancaglini, P | 1 |
| de Oliveira, KT | 1 |
| Chin, A | 1 |
| Hanash, SM | 1 |
| Falcão, RP | 1 |
| Rego, EM | 1 |
| Greene, LJ | 1 |
| Faça, VM | 1 |
| Rahmani, M | 1 |
| Reese, E | 1 |
| Dai, Y | 1 |
| Bauer, C | 1 |
| Payne, SG | 1 |
| Dent, P | 1 |
| Spiegel, S | 1 |
| Grant, S | 1 |
| Berkovic, D | 3 |
| Berkovic, K | 1 |
| Fleer, EA | 4 |
| Eibl, H | 3 |
| Unger, C | 3 |
| Adebodun, F | 1 |
| Post, JF | 1 |
| Goeckenjan, M | 1 |
| Lüders, S | 1 |
| Hiddemann, W | 2 |
| Haase, D | 1 |
| Konstantinov, SM | 1 |
| Topashka-Ancheva, M | 1 |
| Benner, A | 1 |
| Berger, MR | 1 |
| Brochez, V | 1 |
| Van Heuverswyn, D | 1 |
| Diniz, JA | 1 |
| De Potter, CR | 1 |
| Van den Eeckhout, EG | 1 |
| Kötting, J | 1 |
| Neumüller, W | 1 |
| Hochhuth, C | 1 |
| Doenecke, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS[NCT00301938] | Phase 1 | 30 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for phosphorylcholine and Leukemia
| Article | Year |
|---|---|
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2013 |
13 other studies available for phosphorylcholine and Leukemia
| Article | Year |
|---|---|
Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Drug Screening Assays, Antitumor; Humans | 2010 |
Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; E2F1 Trans | 2011 |
Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Do | 2012 |
Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals | 2012 |
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Butyrates; Ce | 2005 |
Inhibition of calcium-dependent protein kinase C by hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL60 and K562 cell lines.
Topics: Antineoplastic Agents; Cell Division; Cell Membrane; Cytosol; Diglycerides; Dose-Response Relationsh | 1994 |
31P NMR characterization of cellular metabolism during dexamethasone induced apoptosis in human leukemic cell lines.
Topics: Adenosine Triphosphate; Apoptosis; Dexamethasone; Ethanolamines; Humans; Hydrogen-Ion Concentration; | 1994 |
Hexadecylphosphocholine inhibits phosphatidylinositol and phosphatidylcholine phospholipase C in human leukemia cells.
Topics: Antineoplastic Agents; Cell Membrane; Cells, Cultured; Chromatography, Thin Layer; Enzyme Activation | 1996 |
Induction of resistance in the human leukemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipid analogues.
Topics: Antigens, Surface; Antineoplastic Agents; Cholesterol; Chromosomes; Drug Resistance, Neoplasm; Flow | 1996 |
Alkylphosphocholines: Effects on human leukemic cell lines and normal bone marrow cells.
Topics: Alkylation; Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Cycle; Cell Division; | 1998 |
Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography.
Topics: Antineoplastic Agents; Breast Neoplasms; Chromatography, Gas; Humans; Leukemia; Phosphorylcholine; R | 1999 |
Antitumoral activity of alkylphosphocholines and analogues in human leukemia cell lines.
Topics: Antineoplastic Agents; Humans; Leukemia; Phosphorylcholine; Tumor Cells, Cultured | 1992 |
Early effects of hexadecylphosphocholine on gene expression in leukemia cell lines.
Topics: Antineoplastic Agents; Humans; Leukemia; Phosphorylcholine; Transcription, Genetic; Tumor Cells, Cul | 1992 |